Ligand Pharmaceuticals, Inc. (LGND)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$285.60-1.43%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Ligand is growing revenue about 22% a year with raised 2026 guidance to $270-$310 million. Profit improved with operating income rising to $17.4 million in Q1 2026. The acquisition of XOMA Royalty will add over 120 assets and diversify growth. Management raised EPS guidance to $8.50-$9.50 for 2026, showing confidence in growth.
The stock trades at a high price-to-earnings ratio of 66.8, well above peers. The company’s guidance is soft and management is volatile. Debt issuance and equity sales may pressure capital allocation. If revenue growth slows below 15%, the growth story weakens.
The market expects about 22% revenue growth and values the stock richly with a price about 13% above consensus and 40% above our fair value. Our fair value is well below the Street median, reflecting caution on valuation and execution risks.
Breaks if: Adjusted EPS falls below $8.50 in FY26
Reaffirm full-year 2026 revenue guidance of $270M-$310M and raise adjusted EPS guidance to $9.00-$9.50, reflecting stronger cost synergies and acquisition benefits.
Stated as a priority in 3 of last 3 quarters. Management reaffirmed and raised 2026 revenue guidance from $245-$285 million in 2025-Q4 to $270-$310 million by 2026-Q2, and adjusted EPS guidance from $8.00-$9.00 to $9.00-$9.50, reflecting stronger cost synergies and acquisition benefits from XOMA. The trajectory shows management delivering on financial guidance upgrades.
“Reaffirming 2026 full-year revenue guidance of $270 million to $310 million and raising adjusted EPS guidance to $9.00 to $9.50.”
“Reaffirming 2026 full-year financial guidance reflecting anticipated partial-year contribution from XOMA acquisition.”
“Reiterating 2026 financial guidance of $245-$285 million in revenues and adjusted EPS of $8.00-$9.00.”
Breaks if: Acquisition fails to close by Q3 2026
Breaks if: Operating income falls below $17 million in Q1 FY2026
Focus on increasing operating income and net income through revenue growth and cost management.
Stated as a priority in 4 of last 4 quarters. Operating income fluctuated, with $54.9M in 2025-Q3 declining to $8.6M in 2026-Q2, while net income improved from $4.8M in 2025-Q2 to $48.5M in 2026-Q2, driven by revenue growth and non-operating income. The trajectory shows mixed operating income but improving net profitability, indicating partial delivery on this priority.
“Net income was $48.5 million, or $2.22 per diluted share, compared with $4.8 million in prior year.”
“Operating income was $17.4 million, net loss of $13.3 million, adjusted net income $34.6 million.”
“Operating income was $13.8 million, net income $44.8 million.”
“Operating income was $54.9 million, net income $117.3 million.”
Breaks if: Annual revenue falls below $270 million in FY26
Reaffirm full-year 2026 revenue guidance of $270M-$310M and raise adjusted EPS guidance to $9.00-$9.50, reflecting stronger cost synergies and acquisition benefits.
Stated as a priority in 3 of last 3 quarters. Management reaffirmed and raised 2026 revenue guidance from $245-$285 million in 2025-Q4 to $270-$310 million by 2026-Q2, and adjusted EPS guidance from $8.00-$9.00 to $9.00-$9.50, reflecting stronger cost synergies and acquisition benefits from XOMA. The trajectory shows management delivering on financial guidance upgrades.
“Reaffirming 2026 full-year revenue guidance of $270 million to $310 million and raising adjusted EPS guidance to $9.00 to $9.50.”
“Reaffirming 2026 full-year financial guidance reflecting anticipated partial-year contribution from XOMA acquisition.”
“Reiterating 2026 financial guidance of $245-$285 million in revenues and adjusted EPS of $8.00-$9.00.”
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity with a focus on the healthcare sector. The current thesis state is intact, supported by recent strong financial results and a successful acquisition, but management execution remains volatile.
The market appears to be pricing in elevated expectations, as indicated by a stretched valuation compared to peers. There is a notable expectations gap, suggesting that investors are anticipating continued strong performance despite mixed execution quality.
Fundamentals may improve as management executes on its priorities, particularly the integration of the XOMA Royalty acquisition. However, there is a moderate risk of earnings misses due to the high-miss-rate nature of the industry.
The thesis hinges on management's ability to maintain or raise guidance in upcoming calls and the overall health of the healthcare sector. Key indicators include performance from sector bellwethers and broader economic conditions affecting jobs and consumer spending.
Over the next 1 to 3 years, LGND's performance will depend on effective management execution and sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Confidence changed from 'high' to 'medium'.
Yes, our read has strengthened. The latest earnings beat supports this improvement. The company reaffirmed and raised its 2026 financial guidance, including EPS and revenue. They also acquired XOMA Royalty to boost growth and diversify their portfolio.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.